Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03632954 · ClinicalTrials.gov registry record
Cytal® Wound Matrix and MicroMatrix® Wound Study
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- 37
- Enrollment target
NCT03632954: Clinical Trial study, sponsored by Integra LifeSciences Corporation.
NCT03632954 is a clinical trial that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03632954 was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- 37 participants
- Enrollment target
Study Summary
This is an observational study to assess the safety and efficacy of MicroMatrix® alone or in combination with Cytal® Wound Matrix on primary measures of wound healing.
Primary Outcome
Assess number of participants with completely healed wounds, defined as 100% epithelialization with no drainage.
Interventions
- DEVICE ACell Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-12-11 |
| Est. Completion | 2020-01-27 |
Why NCT03632954 stopped before completion
NCT03632954 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ACell Arm is the first listed.
NCT03632954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03632954 about?
NCT03632954 is a clinical study titled "Cytal® Wound Matrix and MicroMatrix® Wound Study". This is an observational study to assess the safety and efficacy of MicroMatrix® alone or in combination with Cytal® Wound Matrix on primary measures of wound healing.
What is the current status of trial NCT03632954?
This trial is currently terminated. The enrollment target is 37 participants. The study started on 2018-12-11. Estimated completion is 2020-01-27.
What interventions are being tested in trial NCT03632954?
The interventions under investigation include: ACell Arm (DEVICE).
Who is sponsoring clinical trial NCT03632954?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI